Funding sources Novartis Pharma AG, Basel, Switzerland.
Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study
Article first published online: 18 JAN 2013
© 2012 The Authors. BJD © 2012 British Association of Dermatologists
British Journal of Dermatology
Volume 168, Issue 2, pages 412–421, February 2013
How to Cite
Papp, K.A., Langley, R.G., Sigurgeirsson, B., Abe, M., Baker, D.R., Konno, P., Haemmerle, S., Thurston, H.J., Papavassilis, C. and Richards, H.B. (2013), Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. British Journal of Dermatology, 168: 412–421. doi: 10.1111/bjd.12110
Conflicts of interest See Appendix.
- Issue published online: 30 JAN 2013
- Article first published online: 18 JAN 2013
- Accepted manuscript online: 27 OCT 2012 02:03AM EST
- Accepted for publication 12 October 2012
Fig S1. Plaque psoriasis: role of interleukin-17 in psoriasis pathogenesis in the context of selected cellular and cytokine networks.
Fig S2. Plaque psoriasis: Psoriasis Area and Severity Index 90 achievement, by visit (full analysis set, last observation carried forward).
Table S1. Plaque psoriasis: logistic regression on analysis of Psoriasis Area and Severity Index 50 and 75 achievement during treatment period, by visit (full analysis set, last observation carried forward)
Table S2. Plaque psoriasis:Investigator’s Global Assessment score by visit and treatment(full analysis set, last observation carried forward)
|bjd12110_sm_Suppl-Appendix.doc||48K||Supporting info item|
|bjd12110_sm_FigS1.eps||36487K||Supporting info item|
|bjd12110_sm_FigS2.eps||401K||Supporting info item|
|bjd12110_sm_Suppl-Fig-1.eps||36487K||Supporting info item|
|bjd12110_sm_Suppl-Fig-2.eps||401K||Supporting info item|
|bjd12110_sm_Suppl-tables.doc||89K||Supporting info item|
|bjd12110_sm_TableS1-S2.doc||89K||Supporting info item|
|bjd12110_sm_StudyA2211RichetalSupplAppendixApril2013.doc||157K||Supporting info item|
|bjd12110_sm_StudyA2220PappetalSupplAppendixApril2013.doc||446K||Supporting info item|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.